GlassScriptPhysician profile
Annie Liu
NPI 1982319380
$7,375.36
in general payments reported to CMS, 2019-2025
21 companies · $4,466 in 2025
The $4,466 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $215 · 2024: $2,695 · 2025: $4,466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,782 · Consulting Fee: $1,300 · Travel and Lodging: $178 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,782.05 |
| Consulting Fee | $1,300.00 |
| Travel and Lodging | $178.46 |
| Education | $114.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,720.01 | 2024-2025 | Bimzelx |
| Dermavant Sciences, INC. | $1,464.13 | 2023-2024 | Vtama, Tapinarof |
| Galderma Laboratories, L.P. | $794.17 | 2024-2025 | Aklief, Nemluvio |
| Pfizer INC. | $611.87 | 2024-2025 | |
| Botanix Sb INC | $433.03 | 2025 | Sofdra |
| Arcutis Biotherapeutics, INC. | $347.52 | 2024-2025 | Zoryve |
| Incyte Corporation | $319.92 | 2023-2025 | Opzelura |
| Leo Pharma INC. | $255.57 | 2024-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $255.45 | 2023-2025 | |
| Janssen Biotech, INC. | $186.29 | 2025 | Tremfya |
| Abbvie INC. | $173.26 | 2023-2025 | |
| Almirall LLC | $157.85 | 2025 | Klisyri, Seysara |
| Novo Nordisk INC | $121.82 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $108.36 | 2024-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $92.70 | 2024-2025 | Sotyktu |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $82.67 | 2024-2025 | Otezla |
| Revance Therapeutics, INC. | $66.79 | 2024 | Daxxify |
| Novartis Pharmaceuticals Corporation | $56.91 | 2024 | |
| Organon LLC | $55.21 | 2025 | Vtama |
| Sun Pharmaceutical Industries INC. | $42.40 | 2023 | Absorica Ld, Winlevi |
| Lilly USA, LLC | $29.43 | 2023 | Olumiant, Taltz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annie Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.